You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Medtronic
McKesson
AstraZeneca
Harvard Business School

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

RETIN-A MICRO Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Retin-a Micro patents expire, and what generic alternatives are available?

Retin-a Micro is a drug marketed by Valeant Intl and is included in one NDA.

The generic ingredient in RETIN-A MICRO is tretinoin. There are twenty-six drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the tretinoin profile page.

US ANDA Litigation and Generic Entry Outlook for Retin-a Micro

A generic version of RETIN-A MICRO was approved as tretinoin by PERRIGO PHARMA INTL on December 24th, 1998.

  Start Trial

Paragraph IV (Patent) Challenges for RETIN-A MICRO
Tradename Dosage Ingredient NDA Submissiondate
RETIN-A-MICRO GEL;TOPICAL tretinoin 020475 2010-12-20
RETIN-A MICRO GEL;TOPICAL tretinoin 020475 2010-12-20
RETIN-A-MICRO GEL;TOPICAL tretinoin 020475 2010-07-08
RETIN-A MICRO GEL;TOPICAL tretinoin 020475 2010-07-08

US Patents and Regulatory Information for RETIN-A MICRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Intl RETIN-A MICRO tretinoin GEL;TOPICAL 020475-002 May 10, 2002 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Valeant Intl RETIN-A MICRO tretinoin GEL;TOPICAL 020475-001 Feb 7, 1997 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RETIN-A MICRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Intl RETIN-A MICRO tretinoin GEL;TOPICAL 020475-002 May 10, 2002   Start Trial   Start Trial
Valeant Intl RETIN-A MICRO tretinoin GEL;TOPICAL 020475-001 Feb 7, 1997   Start Trial   Start Trial
Valeant Intl RETIN-A MICRO tretinoin GEL;TOPICAL 020475-002 May 10, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for RETIN-A MICRO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 1390049-3 Sweden   Start Trial PRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
1304992 122013000081 Germany   Start Trial PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322
1304992 CR 2013 00053 Denmark   Start Trial PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Express Scripts
AstraZeneca
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.